Roots Analysis has done a detailed study on Global Autoinjectors Market (3rd Edition), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
To order this 600+ page report, which features 360+ figures and 350+ tables, please visit this link
Key Market Insights
- Currently, several companies claim to be engaged in the development / manufacturing of various types of autoinjectors, most of which are disposable systems that use prefilled syringes as primary drug containers
- About 90 autoinjector-based combination products have been approved for the treatment of a variety of clinical conditions; the subcutaneous route being the preferred mode of drug delivery via such devices
- In order to gain a competitive edge in the market, many autoinjector manufacturers are focusing on the integration of advanced features into their respective products and affiliated offerings
- Over time, more than 4,600 patents have been filed / granted related to autoinjectors and affiliated products; most of the new intellectual property is related to additional features, such as safety locks and device connectivity
- Eminent scientists from renowned organizations and academic institutions across the world have made valuable contributions to this field, in terms of leading clinical research efforts and developing novel technologies
- Several autoinjector developers have established strong brand positions in different geographies; the focus, in the near term, is likely to be on further enhancing device features for better disease management and improved patient compliance
- An evaluation of 200+ marketed and pipeline products revealed that a variety of drugs / product candidates are likely to be considered for administration via autoinjectors in the near future
- Case Study: Owing to the complexities associated with the manufacturing and assembly of autoinjector drug delivery systems, industry players are known to frequently engage the services of contract service providers
- Currently, disposable autoinjector products for small molecule drugs dominate the market; however, in the foreseen future, the demand for reusable devices is anticipated to witness significant growth
- Given the recent approvals and presence of multiple drug candidates in later stages of development, the market opportunity is likely to be distributed across different therapeutic areas, routes of administration and geographies
For more information, please visit https://www.rootsanalysis.com/reports/view_document/autoinjectors-market/293.html
Table of Contents
- PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
- EXECUTIVE SUMMARY
- INTRODUCTION
3.1. Chapter Overview
3.2. Types of Drug Delivery Systems
3.3. Drawbacks of Conventional Parenteral Delivery Systems
3.4. Needlestick Injuries
3.4.1. Incidence and Cost Burden
3.4.2. Government Legislation for the Prevention of Needlestick Injuries
3.5. Emerging Trend of Self-Administration
3.5.1. Rising Burden of Chronic Diseases
3.5.2. Healthcare Cost Savings
3.5.3. Need for Immediate Treatment in Emergency Situations
3.5.4. Growth of Injectable Biologics Market
3.5.5. Addressing Key User Safety Requirements
3.6. Types of Self- Administration Devices
3.6.1. Prefilled Syringes
3.6.2. Pen-Injectors
3.6.3. Needle-Free Injectors
3.6.4. Autoinjectors
3.6.5. Large Volume Wearable Injectors
3.7. Overview of Autoinjectors
3.7.1. Components of Autoinjectors
3.7.2. Classification of Autoinjectors
3.7.2.1. On the Basis of Mechanism of Action
3.7.2.2. On the Basis of Usability
3.7.2.3. On the Basis of Type of Dose
3.7.3. Manufacturing / Packaging of Autoinjectors
3.7.4. Benefits of Autoinjectors
3.8. Regulatory Considerations
3.8.1. Medical Devices
3.8.2. Drug Device Combination Products
3.9. Future Perspectives
- PRIMARY DRUG CONTAINERS
4.1. Chapter Overview
4.2. Types of Packaging
4.3. Introduction to Primary Drug Containers
4.3.1. Role of Primary Drug Containers
4.3.2. Types of Primary Drug Containers
4.3.2.1. Cartridges
4.3.2.1.1. Components of Cartridges
4.3.2.1.2. Types of Cartridges
4.3.2.1.2.1. Single Chamber Cartridge
4.3.2.1.2.2. Dual Chamber Cartridge
4.3.2.1.3. Cartridges Available in the Market
4.3.2.2. Syringes
4.3.2.2.1. Components
4.3.2.2.2. Types of Syringes
4.3.2.2.2.1. Based on Number of Chambers
4.3.2.2.2.2. Based on Type of Needle
4.3.2.2.3. Prefilled Syringe Systems Available in the Market
4.3.2.2.3.1. Glass Prefilled Syringes
4.3.2.2.3.2. Plastic Prefilled Syringes
4.3.2.3. Vials
4.3.2.3.1. Components
4.3.2.3.2. Vials Available in the Market
4.4. Comparison of Fabrication Materials
- AUTOINJECTORS: CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Autoinjectors: List of Devices
5.2.1. Analysis by Usability
5.2.2. Analysis by Type of Primary Container
5.3. Autoinjectors: List of Additional Parameters of Devices
5.3.1. Analysis by Volume of Container
5.3.2. Analysis by Type of Dose
5.3.3. Analysis by Route of Administration
5.3.4. Analysis by Actuation Mechanism
5.3.5. Analysis by Type of Feedback Mechanism
5.4. Autoinjectors: List of Developers
5.4.1. Analysis by Year of Establishment
5.4.2. Analysis by Company Size
5.4.3. Analysis by Geographical Location of Headquarters
- PRODUCT COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology
6.3. Assumptions and Key Parameters
6.4. Product Competitiveness Analysis
6.4.1. Disposable Autoinjectors
6.4.2. Reusable Autoinjectors
- BRAND POSITIONING ANALYSIS OF KEY INDUSTRY PLAYERS
7.1 Chapter Overview
7.2. Scope and Methodology
7.3. Brand Positioning Matrix: Antares Pharma
7.4. Brand Positioning Matrix: BD
7.5. Brand Positioning Matrix: DALI Medical Devices
7.6. Brand Positioning Matrix: Elcam Drug Delivery Devices
7.7. Brand Positioning Matrix: Oval Medical Technologies
7.8 Brand Positioning Matrix: Owen Mumford
7.9. Brand Positioning Matrix: SHL Medical
7.10 Brand Positioning Matrix: Union Medico
7.11. Brand Positioning Matrix: Ypsomed
- PATENT ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Autoinjectors: Patent Analysis
8.3.1. Analysis by Application Year
8.3.2. Analysis by Issuing Authority
8.3.3. Analysis by CPC Symbols
8.4. Emerging Areas
8.5. Leading Players Based on Number of Patents
8.6. Autoinjectors: Patent Benchmarking Analysis
8.6.1. Analysis by Patent Characteristics
8.6.2. Analysis by Geography
8.7. Autoinjectors: Patent Valuation Analysis
- THERAPEUTIC PRODUCTS AVAILABLE IN AUTOINJECTORS
9.1. Chapter Overview
9.2. Autoinjector Combination Products: List of Approved Drugs
9.2.1. Analysis by Initial Year of Approval
9.2.2. Analysis by Usability
9.2.3. Analysis by Route of Administration
9.2.4. Analysis by Primary Drug Container
9.3. Approved Autoinjector Combination Products: List of Additional Parameters
9.3.1. Analysis by Type of Molecule
9.3.2. Analysis by Dose Strength
9.3.3. Analysis by Therapeutic Indication
9.3.4. Analysis by Other Packaging Formats of Marketed Drugs
9.4. Autoinjector Combination Products: List of Pipeline Drugs
9.4.1. Analysis by Phase of Development
9.5. Pipeline Autoinjector Combination Products: List of Additional Parameters
9.5.1. Analysis by Route of Administration
9.5.2. Analysis by Type of Molecule
9.5.3. Analysis by Therapeutic Indication
9.5.4. Grid Analysis: Distribution by Therapeutic Indication, Phase of Development and Route of Administration
9.6. Autoinjector Combination Products: List of Developers
9.6.1. Analysis by Year of Establishment
9.6.2. Analysis by Company Size
9.6.3. Analysis by Location of Headquarters
- CASE STUDY: AUTOINJECTOR-BASED COMBINATION PRODUCTS AND AFFILIATED THERAPEUTIC AREAS
10.1. Chapter Overview
10.2. Marketed / Pipeline Drugs Being Evaluated with Autoinjectors
10.3. Case Study I: Anaphylaxis
10.3.1. Overview and Epidemiology
10.3.2. Adrenaline: Mechanism of Action
10.3.3. History of Development
10.3.4. Marketed Adrenaline / Epinephrine Autoinjectors
10.3.4.1. Adrenaclick
10.3.4.2. Allerject / Auvi-Q (Formerly called e-cue)
10.3.4.3. Anapen
10.3.4.4. Emerade
10.3.4.5. EpiPen / EpiPen Jr
10.3.4.6. Jext
10.3.4.7. EpiPen / EpiPen Jr
10.3.5. Adrenaline / Epinephrine Autoinjectors Under Development
10.3.5.1. EpiQ
10.3.5.2. ANDIPen
10.3.5.3. MiniEpi
10.3.5.4. Zeneo Adrenaline
10.3.6. Other Dosage Forms
10.3.7. Historical Sales of Approved Drugs / Autoinjectors
10.4. Case Study II: Multiple Sclerosis
10.4.1. Overview and Epidemiology
10.4.2. Interferon β-1a
10.4.3. Interferon β-1b
10.4.4. Interferons: Mechanism of Action
10.4.5. History of Development
10.4.6. Interferon β-1a Autoinjectors
10.4.6.1. Avonex Pen
10.4.6.2. PLEGRIDY Pen
10.4.6.3. Rebif Rebidose
10.4.6.4. RebiSmart
10.4.6.5. Rebiject II
10.4.6.6. ReciGen Physioject
10.4.7. Interferon β-1b Autoinjectors
10.4.7.1. BETACONNECT
10.4.7.2. BETAJECT Comfort / Betacomfort
10.4.7.3. Betaject Lite
10.4.7.4. ExtaviJect 30G / ExtaviPro 30G
10.4.8. Other Marketed Autoinjectors
10.4.8.1. Cinnomer40 Physioject
10.4.8.2. CSYNC Autoinjector
10.4.8.3. WhisperJECT
10.4.8.4. Remurel Autoxon
10.4.9. Other Dosage Forms
10.4.10. Historical Sales of Approved Drugs / Autoinjectors
10.4.10.1. Interferon β-1a
10.4.10.2. Interferon β-1b
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
